

INDO-BANGLA PHARMACEUTICALS PLC

Un-Audited Financial Statements

For the Period ended 30th September, 2025

Table of Contents

Serial No.	Particulars	Page No.
01	Statement of Financial Position	01
02	Statement of Profit or Loss and Other Comprehensive Income	02
03	Statement of Changes in Equity	03
04	Statement of Cash Flows	04
05	Notes to the Financial Statements	05-22
06	Property, Plant & Equipment (Annexure-A)	23


INDO-BANGLA PHARMACEUTICALS PLC
STATEMENT OF FINANCIAL POSITION (Un-Audited)
As at 30 September, 2025


Particulars	Notes	Amounts in Taka	
		30 September 2025	30 June 2025
ASSETS:			
Non-current Assets:		1,291,404,203	1,298,261,253
Property, Plant and Equipment	3.00	1,257,724,506	1,264,563,706
Intangible Assets	4.00	458,150	476,000
Capital Work In Progress	5.00	33,221,547	33,221,547
Current Assets:		451,732,337	425,847,942
Inventories	6.00	113,057,601	103,569,933
Trade & Other Receivables	7.00	217,033,521	196,238,245
Advance, Deposits and Prepayments	8.00	118,738,518	121,696,790
Cash and Cash equivalents	9.00	2,902,698	4,342,975
TOTAL ASSETS		1,743,136,540	1,724,109,195
EQUITY AND LIABILITIES			
Shareholders' Equity:		1,457,506,683	1,456,282,611
Share Capital	10.00	1,162,051,780	1,162,051,780
Retained Earnings	11.00	295,454,903	294,230,831
NON-CURRENT LIABILITIES		151,891,937	150,241,186
Deferred Tax Liability	12.00	151,891,937	150,241,186
Current Liabilities:		133,737,919	117,585,399
Short Term Loan	13.00	19,100,000	20,000,000
Unclaimed Dividend	14.00	14,865,193	14,800,807
Trade Payables and Other Payable	15.00	18,305,820	18,473,871
Advance from Customer	16.00	17,283,970	-
Provision for Taxes	17.00	52,244,157	51,828,396
Liabilities for Expenses	18.00	11,938,780	12,482,325
Total Liabilities		285,629,856	267,826,586
TOTAL OWNER'S EQUITY AND LIABILITIES		1,743,136,540	1,724,109,195
Net Asset Value (NAV) Per Share		12.54	13.58

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Date: 15 January, 2026
Dhaka

INDO-BANGLA PHARMACEUTICALS PLC

STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Un-Audited)


For the first quarter ended 30th September, 2025


Particulars	Notes	Amount In BDT	
		30 September 2025	30 September 2024
Net Sales Revenue	18.00	41,576,097	27,732,408
Less: Cost of Sales	19.00	28,783,003	22,839,814
Gross Profit		12,793,094	4,892,594
Less: Operating Expenses:		9,337,979	5,508,495
Administrative Expenses	20.00	6,887,285	3,739,548
Financial Expenses	21.00	1,095,595	945,922
Selling & Distributing Expenses	22.00	1,355,099	823,025
Profit from Operations		3,455,114	(615,901)
Add: Non Operating Income:	23.00	-	50,000
Profit before Contribution to WPPF & Welfare Fund		3,455,114	(565,901)
Less: Contribution to WPPF & Welfare Fund		164,529	-
Profit before Tax		3,290,585	(565,901)
Less: Income Tax Expenses:		2,066,512	2,445,543
Current Tax	24.00	415,761	176,394
Deferred Tax	12.00	1,650,751	2,269,149
Net Profit for the year		1,224,073	(3,011,444)
Earnings per share (EPS)	25.00	0.01	(0.03)

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Date: 15 January, 2026
Dhaka

INDO-BANGLA PHARMACEUTICALS PLC
STATEMENT OF CHANGES IN EQUITY (Un-Audited)
For the first quarter ended 30th September, 2025

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 30-06-2025	1,162,051,780	294,230,830	1,456,282,610
Net Profit for the period	-	1,224,073	1,224,073
Balance as at 30-09-2025	1,162,051,780	295,454,903	1,457,506,683


INDO-BANGLA PHARMACEUTICALS PLC
STATEMENT OF CHANGES IN EQUITY
For the first quarter ended 30th September 2024

Particulars	Share Capital	Retained Earnings	Total Equity
Balance as at 30-06-2024	1,162,051,780	418,791,168	1,580,842,948
Net Profit for the period	-	(3,011,444)	(3,011,444)
Balance as at 30-09-2024	1,162,051,780	415,779,724	1,577,831,504

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Date: 15 January , 2026

Dhaka

INDO-BANGLA PHARMACEUTICALS PLC


STATEMENT OF CASH FLOWS (Un-Audited)


For the Period ended 30th September, 2025


Particulars	Notes	Amount in Taka	
		30 September 2025	30 September 2024
Cash Flows from Operating Activities			
Cash receipts from customers	28.00	38,064,791	13,157,846
Cash receipts from others income	29.00	-	50,000
Cash payment to Suppliers	30.00	(25,653,819)	(11,483,650)
Cash payment to Employees		(5,560,180)	(5,588,761)
Cash payment to Others		(4,938,612)	(3,033,955)
Cash Generate from operation		1,912,180	(6,898,520)
Cash payment against income Tax		-	-
Net Cash generated from Operating Activities	31.00	1,912,180	(6,898,520)
Cash Flow from Investing Activities			
Acquisition of property, plant and equipment		-	-
Net Cash used in Investing Activities		-	-
Cash Flows from Financing Activities			
Short Term Loan		(900,000)	2,816,193
Paid for Interest on Loan		(2,516,844)	-
Paid for other financing activities		64,386	(806,940)
Paid for Dividend Previous Year		-	-
Net Cash Used in Financing Activities		(3,352,458)	2,009,253
Net increase/(Decrease) in Cash and Cash equivalents		(1,440,278)	(4,889,267)
Cash and Cash Equivalents at beginning of the period		4,342,975	10,395,429
Cash and Cash Equivalent at end of the Period		2,902,698	5,506,162
Net Operating Cash Flows Per Share (NOCFPS)		0.02	(0.06)

Annexed notes form an integral part of these financial statements.


Chief Financial Officer


Company Secretary


Director


Managing Director


Chairman

Date: 15 January , 2026

Dhaka